文献速递前列腺癌

利用空间追踪MRI/超声引导活检识别单侧前列腺癌

Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer.
PubMed 文献 · BJU Int · 2019-11-25

本研究利用融合设备的空间追踪数据构建决策树,以预测前列腺癌的单侧性,从而改进半腺消融的患者选择。研究纳入173例接受MRI/超声引导活检和根治性前列腺切除术的患者,决策树模型AUC为0.82,将标准诊断的单侧识别错误率从47%降至17%(P=0.01)。

要点

  • 决策树模型识别前列腺癌单侧性的AUC为0.82。
  • 标准诊断错误识别单侧病变的比例为47%,决策树降至17%(P=0.01)。
  • 肿瘤距中线7 mm以内(40 mL前列腺)或中央三分之一半径内者不宜行半腺消融。

核心结论

  • 利用融合设备空间追踪构建的决策树在识别前列腺癌单侧性方面比标准诊断更可靠。
  • 肿瘤位于前列腺半径中央三分之一内者因中线延伸风险不适合半腺消融。

研究设计与样本

  • 单中心回顾性研究,纳入2011至2018年接受MRI/超声引导活检和根治性前列腺切除术的患者173例。
  • 使用分类与回归树(CART)分析构建决策树,评估模型判断的侧别与最终手术病理的一致性。

主要发现

  • 决策树模型的AUC为0.82。
  • 标准诊断和决策树正确识别疾病侧别的比例分别为73%和80%(P=0.13)。
  • 标准诊断判定为单侧的患者中,47%存在未检测到的对侧病变或识别错误。
  • 决策树将错误率降至17%(P=0.01)。

关键数值与推荐

  • 除活检和MRI确认的单侧病变外,应对40 mL前列腺内距中线7 mm以内的癌症进行进一步筛查,这相当于任何大小前列腺半径的中央三分之一。

临床怎么用

  • 对于考虑半腺消融的前列腺癌患者,可使用基于融合设备空间追踪的决策树辅助判断单侧性。
  • 若肿瘤位于前列腺半径中央三分之一内,应避免半腺消融以降低中线延伸风险。

局限性

  • 单中心回顾性研究,样本量173例,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To create reliable predictive metrics of unilateral disease using spatial tracking from a fusion device, thereby improving patient selection for hemi-gland ablation of prostate cancer. PATIENTS AND METHODS: We identified patients who received magnetic resonance imaging (MRI)/ultrasound-guided biopsy and radical prostatectomy at a single institution between 2011 and 2018. In addition to standard clinical features, we extracted quantitative features related to biopsy core and MRI target locations predictive of tumour unilaterality. Classification and Regression Tree (CART) analysis was used to create a decision tree (DT) for identifying cancer laterality. We evaluated concordance of model-determined laterality with final surgical pathology. RESULTS: A total of 173 patients were identified with biopsy coordinates and surgical pathology available. Based on CART analysis, in addition to biopsy- and MRI-confirmed disease unilaterality, patients should be further screened for cancer detected within 7 mm of midline in a 40 mL prostate, which equates to the central third of any-sized prostate by radius. The area under the curve for this DT was 0.82. Standard diagnostics and the DT correctly identified disease laterality in 73% and 80% of patients, respectively (P = 0.13). Of the patients identified as unilateral by standard diagnostics, 47% had undetected contralateral disease or were otherwise incorrectly identified. This error rate was reduced to 17% (P = 0.01) with the DT. CONCLUSION: Using spatial tracking from fusion devices, a DT was more reliable for identifying laterality of prostate cancer compared to standard diagnostics. Patients with cancer detected within the central third of the prostate by radius are poor hemi-gland ablation candidates due to the risk of midline extension of tumour.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Zhou SR, Priester AM, Jayadevan R, et al. Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer. BJU Int. 2019. PMID: 31680423. doi:10.1111/bju.14943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。